<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610827</url>
  </required_header>
  <id_info>
    <org_study_id>20-007655</org_study_id>
    <nct_id>NCT04610827</nct_id>
  </id_info>
  <brief_title>Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder</brief_title>
  <official_title>Optimum Frequency and Timing of Oral Iron Administration for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see if the level of serum ferritin differs based on&#xD;
      how often oral iron (in the form of ferrous sulfate) is given to children with restless leg&#xD;
      syndrome/periodic limb movement disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ferritin level</measure>
    <time_frame>Baseline, 2 months</time_frame>
    <description>Ferritin level in blood measured in micrograms per liter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Side effects</measure>
    <time_frame>2 months</time_frame>
    <description>Number of subjects to experience side effects effects (e.g., stool color change, nausea, constipation, teeth staining)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sleep Disorder</condition>
  <condition>Restless Legs Syndrome</condition>
  <condition>Periodic Limb Movement Sleep Disorder</condition>
  <condition>Iron-deficiency</condition>
  <arm_group>
    <arm_group_label>Ferrous sulfate daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will take 3 mg/kg oral iron in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferrous sulfate twice daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take 1.5 mg/kg oral iron twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferrous sulfate every other day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 mg/kg oral iron every other day in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous sulfate</intervention_name>
    <description>Guideline-recommended 3 mg/kg/day dosing</description>
    <arm_group_label>Ferrous sulfate daily</arm_group_label>
    <arm_group_label>Ferrous sulfate every other day</arm_group_label>
    <arm_group_label>Ferrous sulfate twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ferritin equal to or lower than 24 mcg/L drawn within the last 30 days.&#xD;
&#xD;
          -  Age 2 to 8 years.&#xD;
&#xD;
          -  Diagnosis of restless leg syndrome, periodic limb movement disorder, or sleep&#xD;
             disturbance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking oral formulation of iron other than a multivitamin.&#xD;
&#xD;
          -  Untreated obstructive sleep apnea.&#xD;
&#xD;
          -  Gastrointestinal disorder, including gastroesophageal refluex disease and celiac&#xD;
             disease.&#xD;
&#xD;
          -  Prior gastrointestinal surgery; e.g., gastrectomy, duodenal bypass, and presence of&#xD;
             G-tube.&#xD;
&#xD;
          -  Use of H2 blocker, antacid, or proton pump inhibitor.&#xD;
&#xD;
          -  Inflammatory disorders, including juvenile idiopathic arthritis or inflammatory bowel&#xD;
             disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suresh Kotagal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Suresh Kotagal</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Nocturnal Myoclonus Syndrome</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

